BPC-157 FDA Status 2026: Is It Approved?
Short answer: no FDA-approved BPC-157 medicine was identified in the sources reviewed for this September 2026 update. The reported July advisory recommendation did not itself authorize compounding. The current record also differs from older Category 2 descriptions: FDA lists BPC-157 under withdrawn nominations. Here is how approval, pharmacy access and the research evidence fit together.
July advisory recommendation: what changed and what did not
AP's July 23 reporting describes favorable 8–6 votes with one abstention for BPC-157, KPV and TB-500. We attribute that tally to the report; we have not independently transcribed FDA's recording. A favorable recommendation is meaningful for the access discussion, but it is not approval or proof of effectiveness. See our PCAC vote results tracker for the wider meeting coverage.
Is BPC-157 FDA Approved?
There is no FDA-approved BPC-157 product identified in the regulatory sources reviewed here. FDA's 2026 BPC-157 briefing confirms that neither the free base nor acetate is a component of an approved drug. That does not establish whether a confidential application has been submitted, and it does not mean BPC-157 has never been studied in people.
Approval of a finished drug is different from early clinical research or a compounding-list decision. Human BPC-157 reports exist, including a small ulcerative-colitis trial reported as a meeting abstract; those reports do not establish an approved treatment or validate every marketed route and use. For the broader picture of which peptides sit where, see our overview of peptides that could become legal to compound again in 2026.
Approved vs Legal: Two Different Questions
Approval, prescribing, compounding, selling and possessing a substance are different questions. A prescription does not create an approved product or automatically satisfy compounding requirements. Likewise, the absence of a controlled-substance restriction would not resolve every federal or state rule about a particular transaction.
For 503A compounding from bulk ingredients, FDA describes monograph, approved-drug-component and bulks-list pathways, alongside a separate conditional interim enforcement policy. A committee recommendation alone changes none of those requirements. The current final 503A bulks list reviewed for this update does not include BPC-157. Our FDA Category 2 explainer walks through the compounding framework in detail.
The 2023 Category 2 Decision (Why Compounding Stopped)
BPC-157 was previously in Category 2, which falls outside FDA's Category 1 interim enforcement-discretion policy. The current FDA safety-risk table instead places it under withdrawn nominations. Withdrawal is not Category 1 placement, finished-drug approval or permission to compound. Describing BPC-157 as still in Category 2 misses this change.
FDA continues to flag possible immune reactions and difficulties characterizing BPC-157 ingredients and impurities, while emphasizing gaps in route-specific safety information. These are concerns and uncertainties, not proof that every exposure causes harm. The 503A framework explains the separate statutory conditions and interim policy. This page cannot establish what every pharmacy supplies or whether a particular preparation meets all applicable requirements. For the wider history, read our FDA peptide ban guide.
The July 23, 2026 PCAC Review
The FDA meeting record identifies BPC-157 free base and acetate for the July 23 session, evaluated for ulcerative colitis. That is a defined disease, not a finding that BPC-157 treats every digestive complaint or sports injury.
FDA expressly describes advisory recommendations as non-binding. The meeting page links the briefings and recordings; the reported vote result above comes from AP's contemporaneous coverage. Keep that result separate from any subsequent agency policy or final regulation.
BPC-157 shares the July 23 session with KPV (wound healing and inflammatory conditions), TB-500 (wound healing), and MOTS-c (obesity and osteoporosis). The full agenda and the July 24 peptides are covered in our PCAC hearing preview.
What the FDA Staff Position Signals
FDA's BPC-specific briefing recommended against inclusion, weighing ingredient characterization, safety information, effectiveness evidence and existing treatment options. The reported favorable committee recommendation differs from that staff assessment; it did not override a binding agency decision.
AP reported peptide-industry connections among several panel participants and described supporters' argument that pharmacy access could improve sourcing. Those perspectives help explain the debate, but neither political support nor an industry connection determines whether a clinical claim is correct. Evaluate the studies, the staff analysis and the final regulatory action separately.
What Actually Changes After July 23
Watch for an actual FDA policy update or final rule, its effective date and its conditions. A favorable advisory recommendation can inform that process but does not implement it. We have not verified a binding eight-to-twelve-month schedule. Notice-and-comment rulemaking and any interim enforcement policy are distinct routes to track.
Ulcerative colitis was the use FDA evaluated for this meeting, not a newly approved indication. The staff briefing expressly notes that inclusion on the bulks list may not be limited to a specific use; any eventual restrictions depend on the actual action adopted. Neither favorable nor unfavorable advice settles the prospects or timing of a separate finished-drug approval application.
The Research-Chemical Reality
A "research use only" label is neither a legal shield for human-drug marketing nor a guarantee of identity, strength or sterility. FDA considers evidence of intended use, not just a disclaimer. Its August 2026 Peak Performance Peptides warning letter illustrates that enforcement position for other peptide products despite research-only labeling. It is not a BPC-157 laboratory test, a court judgment or evidence that every supplier's product is contaminated.
If you are researching the compound, our factual guides on BPC-157 dosage, side effects, and the actual evidence behind its benefits stick to what the research does and does not show.
How BPC-157 Compares to Other Peptides
TB-500, KPV and MOTS-c also appeared on the July 23 agenda, with different evaluated uses and evidence bases. Combining them does not transfer evidence from one to another. BPC-157 and TB-500 are discussed together in our BPC-157 vs TB-500 comparison. What matters on the GLP-1 side is product-specific approval: approved semaglutide and tirzepatide medicines are not equivalent to every powder or compounded preparation carrying those ingredient names.
For the regulatory contrast on the GLP-1 side, see how the FDA is handling compounded semaglutide and tirzepatide differently from research peptides.
What This Means If You Use or Are Considering BPC-157
Ask separately about the evidence for the proposed use, the exact formulation and route, the source's quality records, and the legal basis for supplying it. An online listing, clinician recommendation or favorable committee vote is not enough to answer all four. Pharmacy availability is not the same as regulatory approval.
Discuss personal treatment decisions with a clinician who knows your history. Emerging research and patient reports can inform questions, but do not establish a reliable safety or benefit estimate on their own. This is a U.S. regulatory explainer, not individualized medical or legal advice.
Sport has a separate rulebook. The 2026 WADA Prohibited List, section S0 names BPC-157 as prohibited in and out of competition for athletes subject to those rules.
Frequently Asked Questions About BPC-157
No FDA-approved BPC-157 product was identified in the regulatory sources reviewed for this update. FDA approval of a finished drug is separate from early human research, a pharmacy offering a preparation, or an advisory recommendation about compounding.
Its former Category 2 status put it outside the Category 1 interim enforcement-discretion policy. The current FDA table lists BPC-157 under withdrawn nominations instead. That change does not itself authorize compounding. This page cannot establish what every pharmacy supplies or whether a particular preparation meets all applicable requirements.
AP reported a favorable 8-6 advisory vote with one abstention. FDA evaluated BPC-157 free base and acetate for ulcerative colitis. An advisory recommendation is not FDA drug approval, a final bulks-list rule or immediate authorization to compound. The actual FDA action and its conditions, not a predicted timeline, determine what changes.
No. The review concerns bulk ingredients for compounding, not approval of a finished BPC-157 medicine. Even eventual inclusion on the 503A bulks list would not constitute drug approval. Early human research exists; we cannot infer the existence or absence of a confidential application from the public compounding record.
There is no blanket answer for every sale, import or possession scenario. A research-only label does not make human-drug marketing lawful, and lack of a controlled-substance restriction would not resolve all other requirements. Assess the specific product, intended use, supplier and applicable federal and state rules. For athletes under WADA rules, the 2026 list prohibits BPC-157 at all times under S0.
FDA describes possible immune reactions, ingredient-characterization and impurity concerns, and limited route-specific safety information. Its staff recommended against listing BPC-157 in the July meeting briefing. Those concerns and evidence gaps are not proof that every exposure causes harm; a favorable advisory vote is not proof of safety either.
A prescription does not create an approved BPC-157 product or automatically satisfy compounding and supply requirements. Ask the clinician and dispensing pharmacy to explain the legal basis, exact formulation and quality documentation for the proposed preparation. This page does not provide individualized prescribing or legal clearance.
There are approved finished semaglutide and tirzepatide medicines, including Ozempic, Wegovy, Mounjaro and Zepbound. Approval belongs to those products; it does not extend to every powder or compounded preparation containing the same ingredient. BPC-157 has early human reports but no approved finished medicine identified in the reviewed regulatory sources.